semaglutide bad for kidneys in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial Ozempic for Chronic Kidney Disease:

It can help manage type 2 diabetes symptoms more effectively over time, especially when taken regularly along with lifestyle changes such as proper diet and exercise

Headline results: Mean weight loss: approximately 20.7% in the 7.2 mg arm Placebo arm: typical 13% weight loss The proportion of participants achieving at least 25% weight loss was substantially higher than at 2.4 mg Cardiovascular and glycemic secondary endpoints were consistent with semaglutide class effects Treatment duration in pivotal trials extended through approximately 72 weeks of stable maintenance dosing

Syed at Vital Health Medical Care is highly experienced in prescribing and managing tirzepatide treatment, making her clinic one of the most advanced GLP-1 weight loss centers in the entire Rochester, NY region

The global anti-obesity drug market reflects this success, growing from $3.2 billion in 2024 to an estimated $120 billion by 2034 (a staggering 43.7% compound annual growth rate!)